{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:27:21Z","timestamp":1761920841882,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Science and Technology Project of Fujian Province","award":["2018Y9116","2020J05283"],"award-info":[{"award-number":["2018Y9116","2020J05283"]}]},{"name":"Outstanding Youth Training Program of 900TH Hospital","award":["2019Q03"],"award-info":[{"award-number":["2019Q03"]}]},{"name":"Sailing Project of Fujian Medical University","award":["2019QH1283","2019QH1286"],"award-info":[{"award-number":["2019QH1283","2019QH1286"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10620-021-06856-z","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T22:47:23Z","timestamp":1612910843000},"page":"208-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China"],"prefix":"10.1007","volume":"67","author":[{"given":"Xiao-Jian","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Peng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-Shen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Zhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0001-3672","authenticated-orcid":false,"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"6856_CR1","doi-asserted-by":"publisher","first-page":"e12636","DOI":"10.1111\/hel.12636","volume":"24","author":"F Franceschi","year":"2019","unstructured":"Franceschi F, Covino M, Roubaud Baudron C. Review: Helicobacter pylori and extragastric diseases. Helicobacter 2019;24:e12636","journal-title":"Helicobacter"},{"key":"6856_CR2","first-page":"1778","volume":"83","author":"J Zou","year":"2003","unstructured":"Zou J, Yang ZX. Qin ZM Laboratory and clinical study of levofloxacin against Helicobacter pylori. Zhonghua Yi Xue Za Zhi 2003;83:1778\u20131781","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"6856_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/gutjnl-2011-300495","volume":"61","author":"S Nakamura","year":"2012","unstructured":"Nakamura S, Sugiyama T, Matsumoto T et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: A multicentre cohort follow-up study of 420 patients in Japan. Gut 2012;61:507\u2013513","journal-title":"Gut"},{"key":"6856_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jama.291.2.187","volume":"291","author":"BC Wong","year":"2004","unstructured":"Wong BC, Lam SK, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004;291:187\u2013194","journal-title":"JAMA"},{"key":"6856_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V\/Florence consensus report. Gut 2017;66:6\u201330","journal-title":"Gut"},{"key":"6856_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/hel.12046","volume":"18","author":"P Su","year":"2013","unstructured":"Su P, Li Y, Li H et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter 2013;18:274\u2013279","journal-title":"Helicobacter"},{"key":"6856_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/1751-2980.12498","volume":"18","author":"TS Wu","year":"2017","unstructured":"Wu TS, Hsu PI, Kuo CH et al. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori. J Dig Dis 2017;18:537\u2013542","journal-title":"J Dig Dis"},{"key":"6856_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/imj.13432","volume":"47","author":"PH Katelaris","year":"2017","unstructured":"Katelaris PH, Katelaris AL. A prospective evaluation of levofloxacin-based triple therapy for refractory Helicobacter pylori infection in Australia. Intern Med J 2017;47:761\u2013766","journal-title":"Intern Med J"},{"key":"6856_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00508-010-1404-3","volume":"122","author":"Y Li","year":"2010","unstructured":"Li Y, Huang X, Yao L et al. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: A meta analysis. Wien Klin Wochenschr 2010;122:413\u2013422","journal-title":"Wien Klin Wochenschr"},{"key":"6856_CR10","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/aps.2011.78","volume":"32","author":"L Liu","year":"2011","unstructured":"Liu L, Pan X, Liu HY et al. Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans. Acta Pharmacol Sin 2011;32:1285\u20131293","journal-title":"Acta Pharmacol Sin"},{"key":"6856_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/bdd.600","volume":"29","author":"Y Xiao","year":"2008","unstructured":"Xiao Y, Lu Y, Kang Z et al. Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharm Drug Dispos 2008;29:167\u2013172","journal-title":"Biopharm Drug Dispos"},{"key":"6856_CR12","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1128\/AAC.00393-16","volume":"60","author":"X Yu","year":"2016","unstructured":"Yu X, Wang G, Chen S et al. Wild-type and non-wild-type mycobacterium tuberculosis MIC distributions for the novel fluoroquinolone antofloxacin compared with those for ofloxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother 2016;60:5232\u20135237","journal-title":"Antimicrob Agents Chemother"},{"key":"6856_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1365-2036.2004.01994.x","volume":"20","author":"T Masaoka","year":"2004","unstructured":"Masaoka T, SuzukiKurabayashi HK, Kamiya AG et al. Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. Aliment Pharmacol Ther 2004;20:68\u201373","journal-title":"Aliment Pharmacol Ther"},{"key":"6856_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1523-5378.2006.00436.x","volume":"11","author":"P Bogaerts","year":"2006","unstructured":"Bogaerts P, Berhin C, Nizet H et al. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006;11:441\u2013445","journal-title":"Helicobacter"},{"key":"6856_CR15","first-page":"145","volume":"8","author":"Z Ge","year":"1997","unstructured":"Ge Z, Taylor DEH. pylori DNA transformation by natural competence and electroporation. Methods Mol Med 1997;8:145\u2013152","journal-title":"Methods Mol Med"},{"key":"6856_CR16","doi-asserted-by":"publisher","first-page":"e0160007","DOI":"10.1371\/journal.pone.0160007","volume":"11","author":"AA Trespalacios-Rangel","year":"2016","unstructured":"Trespalacios-Rangel AA, Otero W, Arevalo-Galvis A et al. Surveillance of levofloxacin resistance in Helicobacter pylori isolates in Bogota-Colombia (2009\u20132014). PLoS ONE 2016;11:e0160007","journal-title":"PLoS ONE"},{"key":"6856_CR17","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/ajg.2017.195","volume":"112","author":"PI Hsu","year":"2017","unstructured":"Hsu PI, Tsai FW, Kao SS et al. Ten-day quadruple therapy comprising proton pump inhibitor, bismuth, tetracycline, and levofloxacin is more effective than standard levofloxacin triple therapy in the second-line treatment of Helicobacter pylori infection: A Randomized controlled trial. Am J Gastroenterol 2017;112:1374\u20131381","journal-title":"Am J Gastroenterol"},{"key":"6856_CR18","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.3748\/wjg.v21.i9.2786","volume":"21","author":"YX Zhang","year":"2015","unstructured":"Zhang YX, Zhou LY, Song ZQ et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study. World J Gastroenterol 2015;21:2786\u20132792","journal-title":"World J Gastroenterol"},{"key":"6856_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hel.12178","volume":"20","author":"C Xie","year":"2015","unstructured":"Xie C, Lu NH. Review: Clinical management of Helicobacter pylori infection in China. Helicobacter 2015;20:1\u201310","journal-title":"Helicobacter"},{"key":"6856_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/hel.12031","volume":"18","author":"JW Lee","year":"2013","unstructured":"Lee JW, Kim N, Kim JM et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013;18:206\u2013214","journal-title":"Helicobacter"},{"key":"6856_CR21","doi-asserted-by":"publisher","first-page":"e12475","DOI":"10.1111\/hel.12475","volume":"23","author":"WZ Liu","year":"2018","unstructured":"Liu WZ, Xie Y, Lu H et al. Fifth Chinese national consensus report on the management of Helicobacter pylori infection. Helicobacter 2018;23:e12475","journal-title":"Helicobacter"},{"key":"6856_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/apt.13128","volume":"41","author":"JP Gisbert","year":"2015","unstructured":"Gisbert JP, Romano M, Gravina AG et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015;41:768\u2013775","journal-title":"Aliment Pharmacol Ther"},{"key":"6856_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.dld.2009.06.007","volume":"42","author":"JP Gisbert","year":"2010","unstructured":"Gisbert JP, Perez-Aisa A, Castro-Fernandez M et al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis 2010;42:287\u2013290","journal-title":"Dig Liver Dis"},{"key":"6856_CR24","doi-asserted-by":"publisher","first-page":"260","DOI":"10.4166\/kjg.2016.68.5.260","volume":"68","author":"HM Noh","year":"2016","unstructured":"Noh HM, Hong SJ, Han JP et al. Eradication rate by duration of third-line rescue therapy with levofloxacin after Helicobacter pylori treatment failure in clinical practice. Korean J Gastroenterol 2016;68:260\u2013264","journal-title":"Korean J Gastroenterol"},{"key":"6856_CR25","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.3748\/wjg.v24.i40.4548","volume":"24","author":"TF Lin","year":"2018","unstructured":"Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018;24:4548\u20134553","journal-title":"World J Gastroenterol"},{"key":"6856_CR26","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40265-017-0730-4","volume":"77","author":"AC Marin","year":"2017","unstructured":"Marin AC, Nyssen OP, McNicholl AG et al. Efficacy and safety of quinolone-containing rescue therapies after the failure of non-bismuth quadruple treatments for Helicobacter pylori eradication: systematic review and meta-analysis. Drugs 2017;77:765\u2013776","journal-title":"Drugs"},{"key":"6856_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","volume":"12","author":"DY Graham","year":"2007","unstructured":"Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275\u2013278","journal-title":"Helicobacter"},{"key":"6856_CR28","doi-asserted-by":"publisher","unstructured":"Ma Y, Wang Q, Zhang H, et al. Simultaneous quantification of antofloxacin and its major metabolite in human urine by HPLC-MS\/MS, and its application to a pharmacokinetic study. Biomed Chromatogr 2017;31(9).\u00a0https:\/\/doi.org\/10.1002\/bmc.3962","DOI":"10.1002\/bmc.3962"},{"key":"6856_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1159\/000317581","volume":"56","author":"J Wang","year":"2010","unstructured":"Wang J, Xiao Y, Huang W et al. A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections. Chemotherapy 2010;56:378\u2013385","journal-title":"Chemotherapy"},{"key":"6856_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1523-5378.2006.00415.x","volume":"11","author":"H Miyachi","year":"2006","unstructured":"Miyachi H, Miki I, Aoyama N et al. Primary levofloxacin resistance and gyrA\/B mutations among Helicobacter pylori in Japan. Helicobacter 2006;11:243\u2013249","journal-title":"Helicobacter"},{"key":"6856_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1574-695X.2006.00208.x","volume":"49","author":"K Abdelbaqi","year":"2007","unstructured":"Abdelbaqi K, Menard A, Prouzet-Mauleon V et al. Nucleotide sequence of the gyrA gene of Arcobacter species and characterization of human ciprofloxacin-resistant clinical isolates. FEMS Immunol Med Microbiol 2007;49:337\u2013345","journal-title":"FEMS Immunol Med Microbiol"},{"key":"6856_CR32","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1128\/AAC.50.4.1538-1540.2006","volume":"50","author":"T Nishizawa","year":"2006","unstructured":"Nishizawa T, Suzuki H, Kurabayashi K et al. Gatifloxacin resistance and mutations in gyrA after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob Agents Chemother 2006;50:1538\u20131540","journal-title":"Antimicrob Agents Chemother"},{"key":"6856_CR33","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1086\/428055","volume":"41","author":"RC Owens Jr","year":"2005","unstructured":"Owens RC Jr, Ambrose PG. Antimicrobial safety: Focus on fluoroquinolones. Clin Infect Dis 2005;41:S144\u2013S157","journal-title":"Clin Infect Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-06856-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-021-06856-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-06856-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T19:46:24Z","timestamp":1641584784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-021-06856-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6856"],"URL":"https:\/\/doi.org\/10.1007\/s10620-021-06856-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of 900TH Hospital of PLA. Written informed consent was obtained from all participating patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}